">

Reproducible results with powerful microarray analysis

Advances in reproductive health genetic research has led to the emergence of chromosomal microarray analysis (CMA), which has greatly expanded the capabilities of cytogenetics testing. CMA is an ideal platform for copy number variation (CNV) analysis and molecular cytogenetic research. It is a widely used genetic analysis tool, recommended by American College of Medical Genetics (ACMG) as a first-tier test for postnatal research of unexplained developmental delay, intellectual disability, congenital anomalies, and autism spectrum disorder.

 

Thermo Fisher Scientific offers reliable microarray solutions powered with robust workflows that cytogeneticists trust to improve yield, accuracy, and efficiency.

 

With reproducible results, accurate data interpretation and hands-on support, Thermo Fisher Scientific is your trusted partner from start to finish.

Customer & solutions overview

Raise your productivity to a whole new level

Hip Hip array! The new CytoScan Cytogenetics Suite with a two-day turnaround time, improved coverage, and automated interpretation and reporting capabilities is now available.

Overcoming today's lab challenges with CytoScan HD Accel

Dr. Debbie Black discusses the substantial advancements the new CytoScan HD Accel Array brings such as, two-day turnaround time, improved probe coverage, a new reference model that allows users to obtain more pertinent insights in less time compared to the currently dominant microarray in the market, boosting lab productivity by up to 100%.

Enhance efficiency and productivity in cytogenetic analysis with the CytoScan HD Accel Suite

The informative white paper examines the obstacles in efficiency and productivity that laboratories face when striving to deliver reliable and reproducible results. The all new Applied Biosystems CytoScan HD Accel Suite is designed to help overcome these obstacles.

Determine the genetic cause of disease by application of exon-level array as a complement to exome sequencing

Dr. Benjamin Hilton explains how exon-level arrays have allowed for the evaluation of exon-level CNVs that previously were either difficult to identify or missed entirely by other testing methods.

GeneDx benefits from Hybrid-SNP arrays


Dr. Jeanne Mack and Stephanie Warren from GeneDx discuss saving time and money with a more efficient microarray platform. 

 

Postnatal genetic research: chromosomal microarrays or exome sequencing?

Our latest whitepaper elaborates on the utility of multiple technologies, namely chromosomal microarray analysis (CMA), exome sequencing (ES), and genome sequencing (GS) for optimal outcomes in postnatal genetic testing.

CytoScan arrays

 

 

 

Chromosome Analysis Suite (ChAS) software

 

 

 

">